Prospects and challenges in opioid analgesia for pain management

Current Medical Research and Opinion

Volumn 27, Issue 9, 2011, Pages 1741-1743

  Mercadante, Sebastiano ^a,b  

^a LA MADDALENA CANCER CENTER   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

Author keywords

Breakthrough pain; Cancer pain; Chronic pain; Genetics; Opioids

Indexed keywords

FENTANYL; MORPHINE; NALOXONE; NALOXONE PLUS OXYCODONE; NARCOTIC ANALGESIC AGENT; OXYCODONE; TAPENTADOL; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; BREAKTHROUGH CANCER PAIN; CANCER PAIN; CHRONIC PAIN; CONSTIPATION; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MECHANISM; DRUG OVERDOSE; DRUG RELEASE; DRUG TOLERABILITY; ENDOCRINE DISEASE; HUMAN; HYPERALGESIA; PAIN; PERSONALIZED MEDICINE; PHARMACOGENETICS; REVIEW; TABLET FORMULATION;

ANALGESIA; ANALGESICS; ANALGESICS, OPIOID; BREAKTHROUGH PAIN; DRUG DELIVERY SYSTEMS; DRUG DISCOVERY; HUMANS; PAIN MANAGEMENT; TIME FACTORS;

EID: 80051722308     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2011.602057     Document Type: Review

References (16)

1. Breivik H, Collett B, Ventafridda V, et al. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain 2006;10:287-333
2. Smith AK, Cenzer IS, Knight SJ, et al. The epidemiology of pain during the last 2 years of life. Ann Intern Med 2010;153:563-569
3. Chapman CR, Lipschitz DL, Angst MS, et al. Opioid pharmacotherapy for chronic noncancer pain in the United States: a research guideline for developing an evidence-base. J Pain 2010;11:807-829
4. Kalso E, Simpson KH, Slappendel R, et al. Predicting long-term response to strong opioids in patients with low back pain: findings from a randomized, controlled trial of transdermal fentanyl and morphine. BMC Med 2007;5:39
5. Manchikanti L, Vallejo R, Manchikanti KN, et al. Effectiveness of long-term opioid therapy for chronic non-cancer pain. Pain Physician 2011;14:E133-156
6. Bohnert AS, Valenstein M, Bair MJ, et al. Association between opioid prescribing patterns and opioid overdose-related deaths. JAMA 2011; 305:1315-1321
7. Mercadante S, Portenoy RK. Opioid poorly-responsive cancer pain. Part 1: clinical considerations. J Pain Symptom Manage 2001;21:144-150 (Pubitemid 32156944)
8. Chang G, Chen L, Mao J. Opioid tolerance and hyperalgesia. Med Clin North Am 2007;91:199-211
9. Argoff CE. Clinical implications of opioid pharmacogenetics. Clin J Pain 2010;26: S16-S20
10. Klepstad P, Fladvad T, Skorpen F, et al. Influence from genetic variability on opioid use for cancer pain: a European genetic association study of 2294 cancer pain patients. Pain 2011;152:1139-1145
11. Doehring A, Geisslinger G, Lotsch J. Epigenetics in pain and analgesia: an imminent research field. Eur J Pain 2011;15:11-16
12. Meissner W, Leyendecker P, Mueller-Lissner S, et al. A randomized controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation. Eur J Pain 2009;13:56-64
13. Wade W, Spruill WJ. Tapentadol hydrochloride: a centrally acting oral analgesic. Clin Ther 2009;31:2804-2818
14. Davies A, Dickman A, Reid C, et al. The management of cancer related breakthrough pain: recommendations of a task group of the Association of Palliative Medicine of Great Britain and Ireland. Eur J Pain 2009;13:330-337
15. Mercadante S. The use of rapid onset opioids for breakthrough cancer pain: the challenge of its dosing. Crit Rev Oncol Hematol 2011 Jan 5 [Epub ahead of print]
16. Vissers D, Stam W, Nolte T, et al. Efficacy of intranasal fentanyl spray versus other opioids for breakthrough pain in cancer. Curr Med Res Opin 2010;26:1037-1045